Featured Publications for David Corey, Ph.D.

Regulation of transcription by small RNAs complementary to sequences downstream from the 3? termini of genes.

Inhibition of mutant huntingtin expression by targeting mutant RNA structure.

Ago1 and Ago2 link mammalian transcriptional silencing with RNAi.

Inhibiting transcription of chromosomal DNA using antigene peptide nucleic acids.

Inhibiting gene expression at transcription start sites in chromosomal DNA by antigene RNAs

Allele-selectivity by switching to an miRNA-like RNAi mechanism.

Targeting RNA with synthetic oligonucleotides: Clinical success invites new challenges.

Editorial: Nucleic Acids Research virtual issue dedicated to nucleic acid therapeutics, 2018-2023.

Targeting 3' and 5' untranslated regions with antisense oligonucleotides to stabilize frataxin mRNA and increase protein expression.

The 10th Oligonucleotide Therapy Approved: Golodirsen for Duchenne Muscular Dystrophy.

Trinucleotide Repeat-Targeting dCas9 as a Therapeutic Strategy for Fuchs' Endothelial Corneal Dystrophy.

Quantitative Studies of Muscleblind Proteins and Their Interaction With TCF4 RNA Foci Support Involvement in the Mechanism of Fuchs' Dystrophy.

Expression of TNRC6 (GW182) Proteins Is Not Necessary for Gene Silencing by Fully Complementary RNA Duplexes.

Limits of using oligonucleotides for allele-selective inhibition at trinucleotide repeat sequences - targeting the CAG repeat within ataxin-1.

Efficient Electroporation of Neuronal Cells Using Synthetic Oligonucleotides: Identifying Duplex RNA and Antisense Oligonucleotide Activators of Human Frataxin Expression.

Duplex RNAs and ss-siRNAs Block RNA Foci Associated with Fuchs' Endothelial Corneal Dystrophy.

RNA-Mediated Gene Activation: Identifying a Candidate RNA for Preclinical Development.

Doubts About Therapy for Neurological Diseases With Antisense Oligonucleotides-Reply.

Stable association of RNAi machinery is conserved between the cytoplasm and nucleus of human cells.

HP1BP3, a Chromatin Retention Factor for Co-transcriptional MicroRNA Processing.

Argonaute 2-dependent regulation of gene expression by single-stranded miRNA mimics.

Pathogenic C9ORF72 Antisense Repeat RNA Forms a Double Helix with Tandem C:C Mismatches.

Effect of 2'-O-methyl/thiophosphonoacetate-modified antisense oligonucleotides on huntingtin expression in patient-derived cells.

Recognition of c9orf72 Mutant RNA by Single-Stranded Silencing RNAs.

Synthetic Nucleic Acids and Treatment of Neurological Diseases.

Engineering Duplex RNAs for Challenging Targets: Recognition of GGGGCC/CCCCGG Repeats at the ALS/FTD C9orf72 Locus.

Design and bioinformatics analysis of genome-wide CLIP experiments.

Intramolecular circularization increases efficiency of RNA sequencing and enables CLIP-Seq of nuclear RNA from human cells.

Modulation of Splicing by Single-Stranded Silencing RNAs.

Breakthrough Articles: Putting science first.

Stepping toward therapeutic CRISPR.

Reduced Expression of Argonaute 1, Argonaute 2, and TRBP Changes Levels and Intracellular Distribution of RNAi Factors.

Identification and Validation of miRNA Target Sites Within Nontraditional miRNA Targets.

Analysis of nuclear RNA interference in human cells by subcellular fractionation and Argonaute loading.

Allele-Selective Inhibition of Mutant Atrophin-1 Expression by Duplex and Single-Stranded RNAs.

Exploring the Effect of Sequence Length and Composition on Allele-Selective Inhibition of Human Huntingtin Expression by Single-Stranded Silencing RNAs.

Allele-Selective Inhibition of Expression of Huntingtin and Ataxin-3 by RNA Duplexes Containing Unlocked Nucleic Acid Substitutions.

Digital Quantitation of Potential Therapeutic Target RNAs.

RNA duplexes with abasic substitutions are potent and allele-selective inhibitors of huntingtin and ataxin-3 expression.

Transcriptional silencing by single-stranded RNAs targeting a noncoding RNA that overlaps a gene promoter.

ss-siRNAs allele selectively inhibit ataxin-3 expression: multiple mechanisms for an alternative gene silencing strategy.

Allele-selective inhibition of trinucleotide repeat genes.

Transcriptional silencing by hairpin RNAs complementary to a gene promoter.

Silencing disease genes in the laboratory and the clinic.

Expanding the action of duplex RNAs into the nucleus: redirecting alternative splicing.

Argonaute and the nuclear RNAs: new pathways for RNA-mediated control of gene expression.

Mechanism of allele-selective inhibition of huntingtin expression by duplex RNAs that target CAG repeats: function through the RNAi pathway.

RNA sequencing: platform selection, experimental design, and data interpretation.

Clonal Rett Syndrome cell lines to test compounds for activation of wild-type MeCP2 expression.

Antisense and antigene inhibition of gene expression by cell-permeable oligonucleotide-oligospermine conjugates.

Transcriptional gene silencing in mammalian cells by miRNA mimics that target gene promoters.

Regulation of TFEB and V-ATPases by mTORC1.

Transcriptional regulation by miRNA mimics that target sequences downstream of gene termini.

Allele-selective inhibition of ataxin-3 (ATX3) expression by antisense oligomers and duplex RNAs.

Practical Considerations for Analyzing Antigene RNAs (agRNAs): RNA Immunoprecipitation of Argonaute Protein.

Allele-selective inhibition of mutant huntingtin expression with antisense oligonucleotides targeting the expanded CAG repeat.

Involvement of argonaute proteins in gene silencing and activation by RNAs complementary to a non-coding transcript at the progesterone receptor promoter.

Allele-selective inhibition of huntingtin expression by switching to an miRNA-like RNAi mechanism.

Peptide nucleic acids conjugated to short basic peptides show improved pharmacokinetics and antisense activity in adipose tissue.

Telomerase enzyme inhibition (TEI) and cytolytic therapy in the management of androgen independent osseous metastatic prostate cancer.

Clinical status of duplex RNA.

Activation of LDL receptor expression by small RNAs complementary to a noncoding transcript that overlaps the LDLR promoter.

Minireview: Switching on progesterone receptor expression with duplex RNA.

Effect of chemical modifications on modulation of gene expression by duplex antigene RNAs that are complementary to non-coding transcripts at gene promoters.

Transcriptional regulation by small RNAs at sequences downstream from 3' gene termini.

Allele-selective inhibition of mutant huntingtin by peptide nucleic acid-peptide conjugates, locked nucleic acid, and small interfering RNA.

Cellular localization and allele-selective inhibition of mutant huntingtin protein by peptide nucleic acid oligomers containing the fluorescent nucleobase [bis-o-(aminoethoxy)phenyl]pyrrolocytosine.

The puzzle of RNAs that target gene promoters.

Allele-specific silencing of mutant huntingtin and ataxin-3 genes by targeting expanded CAG repeats in mRNAs.

Predicting potential miRNA target sites within gene promoters.

Telomeres and telomerase: from discovery to clinical trials.

Recognition of chromosomal DNA inside cells by locked nucleic acids.

Antisense transcripts are targets for activating small RNAs.

Activating gene expression in mammalian cells with promoter-targeted duplex RNAs.

Inhibiting gene expression with peptide nucleic acid (PNA)--peptide conjugates that target chromosomal DNA.

Inhibiting gene expression with locked nucleic acids (LNAs) that target chromosomal DNA.

RNA learns from antisense.

Chemical modification: the key to clinical application of RNA interference?

Activating gene expression in mammalian cells with promoter-targeted duplex RNAs

Involvement of AGO1 and AGO2 in mammalian transcriptional silencing.

Effect of DNA modifications on DNA processing by HIV-1 integrase and inhibitor binding: role of DNA backbone flexibility and an open catalytic site.

Progesterone receptor plays a major antiinflammatory role in human myometrial cells by antagonism of nuclear factor-kappaB activation of cyclooxygenase 2 expression.

Small molecule, oligonucleotide-based telomerase template inhibition in combination with cytolytic therapy in an in vitro androgen-independent prostate cancer model.

EuroTIDES 2005--Sixth Annual IBC Conference. Oligonucleotide, RNAi and peptides for the drug development and manufacturing industry.

Silencing gene expression by targeting chromosomal DNA with antigene peptide nucleic acids and duplex RNAs.

Antigene inhibition by peptide nucleic acids and duplex RNAs

Inhibiting gene expression at transcription start sites in chromosomal DNA with antigene RNAs.

Inhibiting transcription of chromosomal DNA with antigene peptide nucleic acids.

Recognition of chromosomal DNA in human cells by peptide nucleic acids and small duplex RNAs.

Major vault protein does not play a role in chemoresistance or drug localization in a non-small cell lung cancer cell line.

Regulating mammalian transcription with RNA.

Calcium liberates PNAs from endosomes.

Inhibiting transcription of chromosomal DNA using antigene RNAs.

Intracellular uptake and inhibition of gene expression by PNAs and PNA-peptide conjugates.

Biodistribution of phosphodiester and phosphorothioate siRNA.

Recognition of chromosomal DNA by PNAs.

Efficient and isoform-selective inhibition of cellular gene expression by peptide nucleic acids.

Challenges for RNAi in vivo.

Validating bioluminescence imaging as a high-throughput, quantitative modality for assessing tumor burden.

Synthesis of peptide nucleic acid-peptide conjugates.

Synthesis of oligonucleotide-peptide and oligonucleotide-protein conjugates.

Telomerase reverse transcriptase (hTERT) mRNA and telomerase RNA (hTR) as targets for downregulation of telomerase activity.

Consequences of telomerase inhibition and combination treatments for the proliferation of cancer cells.

Imaging gene expression using oligonucleotides and peptide nucleic acids.

Transcription activation by a PNA-peptide chimera in a mammalian cell extract.

Inhibition of transcription by bisPNA-peptide conjugates.

Binding of nonphysiological protein and peptide substrates to proteases: differences between urokinase-type plasminogen activator and trypsin and contributions to the evolution of regulated proteolysis.

The synaptic complex of RecA protein participates in hybridization and inverse strand exchange reactions.

RNA interference in mammalian cells by chemically-modified RNA.

Extending recognition by peptide nucleic acids (PNAs): binding to duplex DNA and inhibition of transcription by tail-clamp PNA-peptide conjugates.

Inhibition of telomerase by BIBR 1532 and related analogues.

Telomerase inhibitors: a new option for chemotherapy.

Enhanced strand invasion by peptide nucleic acid-peptide conjugates.

Toward synthetic transcription activators: recruitment of transcription factors to DNA by a PNA-peptide chimera.

Imaging gene expression in the brain in vivo in a transgenic mouse model of Huntington's disease with an antisense radiopharmaceutical and drug-targeting technology.

DNA assembly using bis-peptide nucleic acids (bisPNAs).

Telomerase inhibition, oligonucleotides, and clinical trials.

Non-Watson-Crick interactions between PNA and DNA inhibit the ATPase activity of bacteriophage T4 Dda helicase.

Antisense inhibition of gene expression in cells by oligonucleotides incorporating locked nucleic acids: effect of mRNA target sequence and chimera design.

Telomerase inhibition, telomere shortening, and decreased cell proliferation by cell permeable 2'-O-methoxyethyl oligonucleotides.

Implications of high-affinity hybridization by locked nucleic acid oligomers for inhibition of human telomerase.

Cellular delivery of locked nucleic acids (LNAs).

Synthesis and purification of peptide nucleic acids.

Novel antisense and peptide nucleic acid strategies for controlling gene expression.

Telomerase-dependent reactivation of DNA synthesis in macrophages implies alteration of telomeres.

Lipid-mediated introduction of peptide nucleic acids into cells.

Engineering orthogonal ligand-receptor pairs from "near drugs".

The structure of a Michaelis serpin-protease complex.

Liver cell specific targeting of peptide nucleic acid oligomers.

Inhibition of gene expression inside cells by peptide nucleic acids: effect of mRNA target sequence, mismatched bases, and PNA length.

Locked nucleic acid (LNA): fine-tuning the recognition of DNA and RNA.

A bridge between the RNA and protein worlds? Accelerating delivery of chemical reactivity to RNA and DNA by a specific short peptide (AAKK)(4).

Synthesis, analysis, purification, and intracellular delivery of peptide nucleic acids.

Editorial.

Inhibition of telomerase by 2'-O-(2-methoxyethyl) RNA oligomers: effect of length, phosphorothioate substitution and time inside cells.

Application of PNA and LNA oligomers to chemotherapy.

Morpholino antisense oligonucleotides: tools for investigating vertebrate development.

Strand invasion by mixed base PNAs and a PNA-peptide chimera.

Telomerase: an unusual target for cytotoxic agents.

Negative selectivity and the evolution of protease cascades: the specificity of plasmin for peptide and protein substrates.

Modifying ligand specificity of gene regulatory proteins.

Telomerase inhibition by peptide nucleic acids reverses 'immortality' of transformed human cells.

Enhancing solid phase synthesis by a noncovalent protection strategy-efficient coupling of rhodamine to resin-bound peptide nucleic acids.

Automated synthesis of peptide nucleic acids and peptide nucleic acid-peptide conjugates.

Cellular delivery of peptide nucleic acids and inhibition of human telomerase.

Inhibition of human telomerase in immortal human cells leads to progressive telomere shortening and cell death.

The telomerase challenge - an unusual problem in drug discovery.

Strand invasion by DNA-peptide conjugates and peptide nucleic acids.

Inhibition of telomerase leads to eroded telomeres, reduced proliferation, and cell death

Inhibition of human telomerase by 2'-O-methyl-RNA.

Substrate specificity of prostate-specific antigen (PSA).

Engineering proteins: keeping up with biology.

Engineering novel specificities for ligand-activated transcription in the nuclear hormone receptor RXR.

Directing sequence-specific proteolysis to new targets. The influence of loop size and target sequence on selective proteolysis by tissue-type plasminogen activator and urokinase-type plasminogen activator.

Identification of determinants for inhibitor binding within the RNA active site of human telomerase using PNA scanning.

Distinguishing the specificities of closely related proteases. Role of P3 in substrate and inhibitor discrimination between tissue-type plasminogen activator and urokinase.

Peptide nucleic acids: expanding the scope of nucleic acid recognition.

Optimal subsite occupancy and design of a selective inhibitor of urokinase.

Telomerase: anti-cancer target or just a fascinating enzyme?

Inhibition of human telomerase activity by peptide nucleic acids.

Distinct mechanisms contribute to stringent substrate specificity of tissue-type plasminogen activator.

Enhancement of strand invasion by oligonucleotides through manipulation of backbone charge.

Trypsin specificity increased through substrate-assisted catalysis.

Substrate specificity of tissue type plasminogen activator. Characterization of the fibrin independent specificity of t-PA for plasminogen.

Accelerated hybridization of oligonucleotides to duplex DNA.

Strand invasion by oligonucleotide--nuclease conjugates.

Origins of the specificity of tissue-type plasminogen activator.

Targeting peptide nucleic acid-protein conjugates to structural features within duplex DNA.

Cyclic peptides as proteases: a reevaluation.

Trypsin display on the surface of bacteriophage.

Site-specific cleavage of duplex DNA by a semisynthetic nuclease via triple-helix formation.

Generation of a catalytic sequence-specific hybrid DNase.

Introduction of a metal-dependent regulatory switch into an enzyme.

Generation of a hybrid sequence-specific single-stranded deoxyribonuclease.